|A clinical focus on statins.|
|PMID: 11575709 Owner: NLM Status: MEDLINE|
|Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Furthermore, statins are currently the most potent cholesterol-lowering drugs available. Subanalyses of the LIPID study have shown that patients suffering from unstable angina pectoris had at least the same benefit from statin therapy as did patients after myocardial infarction. Studies, recently published (AVERT or MIRACL) provide more information on the topic of therapy with statins in the early phase of acute coronary syndromes.|
|J Auer; B Eber|
Related Documents :
|10559509 - Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 ...
15465509 - Effects of statins on stroke prevention in patients with and without coronary heart dis...
17697899 - Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
20027659 - Statin therapy decreases myocardial function as evaluated via strain imaging.
14980229 - The next step in cardiovascular protection.
1677109 - Aortic distensibility in patients with isolated hypercholesterolaemia, coronary artery ...
3409519 - Long-term follow-up of patients with left ventricular outflow tract obstruction after c...
10559509 - Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 ...
17470329 - Race-related differences in heart failure therapies: simply black and white or shades o...
|Type: Comparative Study; Journal Article; Review|
|Title: Current opinion in investigational drugs (London, England : 2000) Volume: 2 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2001 Mar|
|Created Date: 2001-09-28 Completed Date: 2001-12-04 Revised Date: 2007-11-15|
Medline Journal Info:
|Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England|
|Languages: eng Pagination: 382-8 Citation Subset: IM|
|IInd Medicine Department with Cardiology and Intensive Care, General Hospital Wels, Austria. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Angioplasty, Transluminal, Percutaneous Coronary
Anticholesteremic Agents / economics, therapeutic use*
Cholesterol / biosynthesis, blood
Cholesterol, LDL / blood, metabolism
Clinical Trials as Topic
Coronary Disease / drug therapy*, metabolism, mortality
Fatty Acids, Monounsaturated / therapeutic use
Heptanoic Acids / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics, therapeutic use*
Indoles / therapeutic use
Lovastatin / therapeutic use
Multicenter Studies as Topic
Myocardial Infarction / drug therapy*, metabolism
Practice Guidelines as Topic
Pravastatin / therapeutic use
Pyrroles / therapeutic use
Quality of Life
Randomized Controlled Trials as Topic
Simvastatin / therapeutic use
|0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fatty Acids, Monounsaturated; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 0/Pyrroles; 110862-48-1/atorvastatin; 57-88-5/Cholesterol; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; 93957-54-1/fluvastatin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclero...
Next Document: S-8921 (Shionogi).